Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus InfectionsGlobeNewsWire • 06/12/24
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis BGlobeNewsWire • 06/06/24
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate DevelopmentsGlobeNewsWire • 05/13/24
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical OfficerGlobeNewsWire • 05/01/24
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) InfectionsGlobeNewsWire • 04/18/24
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate DevelopmentsGlobeNewsWire • 03/20/24
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate MilestonesGlobeNewsWire • 01/05/24
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLDGlobeNewsWire • 11/09/23
Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 11/09/23